Alpha Cognition (ACOG) Asset Writedowns and Impairment (2024)
Alpha Cognition's (ACOG) quarterly Asset Writedowns and Impairment came in at -$39166.0 in Q3 2024, little changed quarter-over-quarter from -$39166.0 in Q2 2024.
Alpha Cognition (ACOG) Asset Writedowns and Impairment (2024) Analysis & Trends
Alpha Cognition's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at -$39166.0 for Q3 2024.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$39166.0 in Q3 2024; TTM through Dec 2024 was -$39166.0, a N/A change from a year earlier, with the FY2024 full-year figure at $39166.0, changed N/A from the prior year.
- Asset Writedowns and Impairment steadied at -$39166.0 in Q3 2024 per ACOG's latest filing, from -$39166.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $39166.0 in Q1 2024 and bottomed at -$39166.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | Alpha Cognition | 144.27 Mn | 78.17 Mn | 2.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -39,166.00 |
| Sep 30, 2024 | -39,166.00 |
| Jun 30, 2024 | -39,166.00 |
| Jun 30, 2024 | -39,166.00 |
| Mar 31, 2024 | 39,166.00 |
| Mar 31, 2024 | 39,166.00 |